右雷佐生联合多柔比星与多柔比星脂质体预防晚期乳腺癌患者化学治疗致心脏毒性成本-效用分析  

Cost-Utility Analysis of Dexrazoxane Combined with Doxorubicin Versus Doxorubicin Liposomes for the Prevention of Chemotherapy-Induced Cardiotoxicity in Patients with Advanced Breast Cancer

作　　者：王陈萍[1] 孟佳佳 王丹丹[1] 乔进[1] 窦志华[1] WANG Chenping;MENG Jiajia;WANG Dandan;QIAO Jin;DOU Zhihua(Affiliated Nantong Hospital 3 of Nantong University·Nantong Third People's Hospital,Nantong,Jiangsu,China 226006)

机构地区：[1]南通大学附属南通第三医院·江苏省南通市第三人民医院,江苏南通226006

出　　处：《中国药业》2024年第19期127-128,I0001-I0004,共6页China Pharmaceuticals

基　　金：江苏省南通市卫生和计划生育委员会青年医学重点人才建设项目[WR2017017];2021年度江苏省药学会-奥赛康医院药学基金科研项目[A202129]。

摘　　要：目的评价右雷佐生联合多柔比星与多柔比星脂质体预防晚期乳腺癌患者化学治疗(简称化疗)致心脏毒性作用的经济性。方法构建右雷佐生联合多柔比星与多柔比星脂质体预防晚期乳腺癌患者化疗致心脏毒性的决策树模型。基于原始文献,提取相关数据进行合并分析和间接比较,获取有效性和安全性数据;结合成本-效用值信息,分别计算2种策略的直接医疗成本和质量调整生命年(QALYs)。采用成本-效用分析法比较这2种策略的经济性,通过敏感性分析对结果进行稳定性验证。结果与多柔比星脂质体组相比,右雷佐生联合多柔比星组的成本更低,QALYs更高。敏感性分析证明结果稳定。结论与多柔比星脂质体相比,右雷佐生联合多柔比星预防晚期乳腺癌患者化疗致心脏毒性的经济性更好。Objective To evaluate the economics of dexrazoxane combined with doxorubicin versus doxorubicin liposomes for the prevention of chemotherapy-induced cardiotoxicity in patients with advanced breast cancer.Methods The decision tree model of dexrazoxan combined with doxorubicin versus doxorubicin liposomes for the prevention of chemotherapy-induced cardiotoxicity in patients with advanced breast cancer was constructed.Combined analysis and indirect comparison were conducted for extracting data from the original literature to obtain the safety data and effectiveness data.Direct medical costs and quality-adjusted life years(QALYs)for the two decisions were calculated by available information about costs-utility value.Cost-utility analysis was used to compare the two strategies.The sensitivity analysis was performed to evaluate the robustness of the results.Results Compared with that of doxorubicin liposomes,the cost of dexrazoxane combined with doxorubicin was lower,while the QALY was higher.Sensitivity analysis indicated the results were robust.Conclusion Compared with doxorubicin liposomes,dexrazoxane combined with doxorubicin was a more economic therapy for the prevention of chemotherapy-induced cardiotoxicity in patients with advanced breast cancer.

关 键 词：右雷佐生 多柔比星 多柔比星脂质体 晚期乳腺癌 心脏毒性 成本-效用分析 

分 类 号：R956[医药卫生—药学] R979.1